Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Revenues are king. Can someone explain the revenue structure of this agreement?
It’s what makes biotechs so frustrating. Seems like a perpetual delay or difficulty gaining traction. But, Feb 2021 is a blink of an eye in my investment timeframe. It’s worth the wait...
What is your anticipated timeframe for the BLA? My fear is the powerful entities keeping this from any FDA approval. Once it becomes readily available for off label indications, big pharma is in trouble...
Stated in last conference call. It’s a targeted marketing campaign within/amongst salesforce clients to raise awareness on that specific platform.
It is not a widespread or international campaign that most are waiting on
Speculation on what’s prompting this move?
That’s pretty accurate. I’ve been slowly accumulating and waiting to see what Q3/Q4 financials look like. Can this tech be converted to solid revs?? We’ll see...
This needs eyes. Either revs or partnerships with guaranteed revs. Otherwise movement is pump related. Which is fine and part of life on the OTC but I’m giving this company more credit than that. CEO needs to breath some life into this
Don’t invest more than you can lose. If shareholders didn’t take advantage of 2 massive runs then that’s on them. I’m a long...green. 200K shares. I bet I’ll be ok.
Verb has its share of struggles but it’s headed in the right direction. They literally just acquired a profitable company that gives them access into a massive market that fits perfectly with interactive tech. But...people can see for themselves.
Weird. Do failing companies acquire other already successful and known companies??
The Verb march continues
The politicians are sick. I’m not here to debate the likelihood of a vaccine, but at this point, I feel like half the country is going to be leary of (or reject) any therapy coming out for Covid. I’m not sure an approval by the U.K. wouldn’t be better for leronlimab. It’s sickening watching these companies working hard to get something to market only to be smeared along the way. I do think ultimately the safety profile and outcomes associated with leronlimab therapy will leave little room to rebut
I sincerely hope the uplist happens very soon. Receiving FDA approval (or equivalent from another country) while limiting investor access on the OTC is a scenario I’d rather not see play out.
It’s weird...almost like a growing company takes work and has challenges along the way. Maybe it’s just easier than I thought.
Oh, ok...better get out soon
Quarter, after quarter, after quarter, after quarter, after quarter growth...
Salesforce integration with joint marketing soon, Microsoft integration, acquisition announcement next, expanding international markets....
Live, CRM, Learn...
It’s easy to find success if you know where to look. Verb will make investors money if you know how to do it
Really hope CEO has some post Labor Day plans to move this pps. It’s been veeeery quiet around here
Wow! Great profits for you recently, nice job.
Keep in mind it’s only a 20 minute presentation. But, I thought the way Rory attempts to tie in what Verb is doing with the frictionless Amazon model is always an effective approach. He gave an overview of verbLive and a short video demo with an actual business that has utilized the tech. It will be the gold standard for online sales especially for entrepreneurs.
The information about verbCRM and Learn was adequate but I do wish they would have a demo for the Learn application and showcase how teachers can be using it to share files and track their students using the platform. But...again only 20 minutes to do this
Other highlights (at least for me) included essentially no need for additional funding/offerings as they have plenty of cash on hand, the Oct 1 launch of the joint marketing campaign with Salesforce, some insight into the Microsoft integration, and closing of the acquisition next week.
Overall it was good. Still...the name of the game is revenues and we’ll see where Q3 puts the company following continued growth
Good presentation overall and I do think the Live, CRM, and Learn products will continue to expand their reach. Verb will only continue to grow it’s customer base and international markets will gobble this interactive technology up. Future is bright
That doesn’t bode well....looks like my DD strategy failed this time
It may not be about Leronlimab tonight...but it will be soon enough. Giving the medical community more/better therapeutic options is a top priority.
Justifiably. I do think they have grant approval based on safety and M2M results. I’m guessing they know one of the other countries reviewing data will bite. In normal circumstances I think the FDA would recommend phase 3 data before consideration, but the pressure is on. If the drug is as safe as we all know it is, you put it in the hands of US prescribers before it gets shipped exclusively overseas
I don’t understand why the lack of marketing here?? Obtaining an actual FDA approval for any indication is like being handed a winning lottery ticket. I guess I don’t understand what continues to cause the drag on this company?? A medication with an approved indication for low libido should be crashing the party
Any thoughts on the prelim 14c??
This company is so far removed from what I thought it would become. But, small cap biotechs are a risky business.
Yup, that’s a boatload. Here’s to your successful DD
Wait, that’s allowed on this board?
I’ll give you my unsolicited prediction because some on here are too timid to put their money down. 12 months out...$8 per share....after 2:1 FS.
Book it
That works for me. Appreciate the information. Just looking for the timeframe for requirements of disclosure...not questioning the partnership
It would be required to be disclosed in Q2 financials, correct?
Penny for your thoughts about what’s holding this back currently? The current pps seems way undervalued IMO
Believe me, I get it. These are hard to predict and the one absolute I’ve learned is to take profits and play with house money along the way. Thinking your investment is going higher is a setup for failure.
I obviously have no idea what is in store here long term. However, the management seems strong and the technology stronger. That doesn’t guarantee success, but it’s 2 strong indications. If this runs a bit, take profits and then sit back and enjoy the ride..
If you’re worried about the pps on the OTC over the next 2 years, nothing I say will makes any difference. With the technology this company has, the government ties it has created, and the exponential growth of the market space it is a part of....they’ll be just fine. Traders/flippers may not be in the best situation, but mid to long term investors will do just fine IMO
Negative operational cash flow....hahaha...ok
I’ll focus on revs indicating growth and continued market share. Multipliers are assigned accordingly
Starting to feel bad for shorts. Start up tech company now with 5 straight quarters of growth, partnership with SF and another with MSFT close behind. International clients, acquisition pending, 17 new clients to date Q3, e-commerce built....
Getting hard to find things to be critical of these days.
This is extremely important information/results. Having a therapeutic option for patients that are clinically deteriorating is the point!!! Keep the patient from progressing to severe. Early intervention to curb disease progression is what physicians need to combat this....
Volume is needed otherwise shorts continue to push this down to cover. Just the name of the game on the OTC. They need a stellar earnings call to drum up interest
Is this real? An open/live Q&A with a Nasdaq CEO during an earnings call? Have you read any public forums?? Most people couldn’t articulate a meaningful question and honestly, let’s not waste time giving crazies an opportunity to embarrass the rest of us that are trying to actually get information out of the call.
Fake news. I’m an average retail investor that sent Rory a respectful email on Friday with questions about verbLive. He emailed me back that night. Seems like a CEO very much in touch with investors
Agree. The last thing CYDY needs is a slap from the SEC. The data and approval will obviously speak for itself
The target is statistically significant. Good versus great is not determined in these trials. If the results show that leronlimab is better than standard of care, that’s a winner. Especially with what we’ve been shown from a safety perspective.
Exactly. It’s really odd how little information or acknowledgement of trial progression is out in the public domain. The fact other therapies are still discussed even after failing to meet primary endpoints is malpractice. However, leronlimab will have a real breakout opportunity this week. We’ll see if it’s Cinderella or falls back into the heap
This is fine and everyone gets the nefarious actions/intent of shorters, but...the company needs to generate larger buying interest. Hire an IR firm and get the volume up because stagnant trading volumes invite shorts and keep new retail investors on the sidelines. This company has entirely too much to offer for it to be lingering where it is
The bulls are getting restless....this is about to run